瑞科生物－Ｂ (2179.HK)

9.200 +0.010 (+0.11%) 收市：03:08PM HKT

瑞科生物－Ｂ

No. 888 Yaocheng Avenue
Medical High-tech District
Taizhou
China

https://www.recbio.cn

版塊: Healthcare
行業: Biotechnology
全職員工: 472

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Yong Liu	CEO, GM & Chairman of the Board	3.09M	無	1973
Ms. Qingqing Chen	Vice GM, CFO, Secretary & Executive Director	2.16M	無	1983
Dr. Kunxue Hong	Chief Scientist & Non-Executive Director	2.18M	無	1965
Dr. Jianping Chen	Vice GM & Executive Director	2.18M	無	1978
Mr. Bu Li	Vice GM & Executive Director	2.16M	無	1977
Mr. Hongjun Zhou	Vice General Manager	無	無	1981
Dr. Jianhui Zhang	Chief Medical Officer	無	無	無
Mr. Lei Zhou	Finance controller	無	無	1986
Ms. Yin Kwan Ho	Joint Company Secretary	無	無	1978

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It also develops ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. Jiangsu Recbio Technology Co., Ltd. was founded in 2011 and is headquartered in Taizhou, the People's Republic of China.

公司管治

截至 無 止，瑞科生物－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。